DDInter298 DDInter1907
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic disease-modifying anti-rheumatic drug (bDMARDs) that is used in the management of various inflammatory conditions that involve the activation of IL-12 and IL-23 signalling pathways. The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and active psoriatic arthritis, alone or in combination with [methotrexate]. In September 2016, ustekinumab was additionally approved for the management of moderate to severe Crohn's disease in selected adult patients. In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. Ustekinumab is currently the first and only approved biologic therapy for ulcerative colitis that targets the interleukin (IL)-12 and IL-23 cytokines. The dosing regimen for ustekinumab is based on the patient's weight and there are intravenous and subcutaneous formulations of the drug based on the dosing schedule and condition being treated. Ustekinumab is commonly marketed under the trade name STELARA. Ustekinumab biosimilars are available in some markets, including Wezlana (ustekinumab-auub) in the US and Jamteki (AVT04) in Canada.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) treats {v} (Disease) brain cancer
brain cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Eribulin
Eribulin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) SOD1
SOD1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is upregulated by {v} (Compound) Budesonide
Budesonide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Isradipine
Isradipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) SLC31A1
SLC31A1 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) MT2A
MT2A {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) treats brain cancer (Disease) and brain cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is treated by Eribulin (Compound) and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds SOD1 (Gene) and SOD1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Carboplatin (Compound) binds SLC31A2 (Gene) and SLC31A2 (Gene) is upregulated by Budesonide (Compound) and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Isradipine (Compound) and Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds SLC31A1 (Gene) and SLC31A1 (Gene) is bound by Bortezomib (Compound) and SLC31A1 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds MT2A (Gene) and MT2A (Gene) is downregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab
Carboplatin (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab